Changchun GeneScience Pharmaceutical Co., Ltd.
PharmaChangchun, Jilin, China · Est. 1993
Changchun GeneScience Pharmaceutical Co., Ltd. is a Chinese biopharmaceutical company specializing in the development and manufacturing of recombinant human growth hormone and other biological drugs.
12
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
21
Indications↗
Distinct diseases across all programs
98
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
12 drugs in development
Approved2
Phase 34
Phase 26
Phase 13
Preclinical3
By Therapeutic Area
top 5
Metabolic & Endocrine
632%
Oncology
211%
Gastroenterology
15%
Ophthalmology
15%
Musculoskeletal
15%
R&D Momentum
71/100
Pipeline Velocity
52/100
Trial Completion Rate
97/100
Pipeline Concentration
30/100
Pipeline Freshness
62/100
Strategic Signals
- ↗Active in Oncology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 9, 2026
Recruiting
Phase IV Clinical Study Evaluating Efficacy and Safety of Recombinant Human Growth Hormone Injection for Adult Short Bowel Syndrome
Jul 7, 2026
Recruiting
A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial in Healthy Adult Participants in China to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of GenSci144
Earlier
Jun 24, 2026TrialA Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)
Apr 23, 2026TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics of GenSci161 in Healthy Adult Participants
Apr 20, 2026TrialGS1-144 in Participants With Hepatic Impairment and Healthy Female
Mar 16, 2026TrialA Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.
Mar 14, 2026TrialGenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.
Mar 6, 2026TrialA Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD)
4 more events
Mar 6, 2026TrialA Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS)
Feb 1, 2026TrialPhase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD
Jan 10, 2026TrialNanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
Jan 7, 2026TrialA Study（Phase I）of GS3-007a Dry Suspension in Healthy Chinese Adults
Details
Company Info
Therapeutic Focus
Growth hormonePeptidesBiologics
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Gastroenterology(1 drug)
—
—
—
1
—
Gastroenterology(1 drug)
Metabolic & Endocrine(6 drugs)
—
1
3
1
1
Metabolic & Endocrine(6 drugs)
Musculoskeletal(1 drug)
1
—
—
—
—
Musculoskeletal(1 drug)
Oncology(2 drugs)
1
—
1
2
—
Oncology(2 drugs)
Ophthalmology(1 drug)
—
1
—
—
—
Ophthalmology(1 drug)
Unknown / Other(8 drugs)
1
1
5
1
1
Unknown / Other(8 drugs)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)